Institute for Clinical and Economic Review (ICER)
Temiwunmi Akinmuleya Shobanke is a Program Manager at the Institute for Clinical and Economic Review (ICER) since July 2024, responsible for coordinating health technology assessment reviews for new drug therapies with a focus on health policy and equity. Previously, Temiwunmi held roles as a Graduate Teaching Fellow and Research Assistant at Harvard T.H. Chan School of Public Health from August 2022 to August 2024, conducting literature reviews and case studies in public health leadership. Additional experience includes working as a Healthcare Consultant at Analysis Group in mid-2023, serving as a Medical Strategy and Regulatory Affairs Associate at Sanofi from July 2021 to July 2022, and practicing as a Clinical Pharmacist at National Orthopaedic Hospital Igbobi Lagos from September 2019 to August 2020. Temiwunmi earned a Master of Science in Global Health and Population from Harvard T.H. Chan School of Public Health in May 2024, following a Bachelor of Pharmacy in Pharmaceutical Sciences from the University of Ibadan in 2019.
This person is not in any teams
Institute for Clinical and Economic Review (ICER)
The Institute for Clinical and Economic Review (ICER) is an independent, non-profit research institute that conducts evidence-based reviews of health care interventions, including prescription drugs, other treatments, and diagnostic tests. In collaboration with patients, clinical experts, and other key stakeholders, ICER analyzes the available evidence on the benefits and risks of these interventions to measure their value and suggest fair prices. ICER also regularly reports on the barriers to care for patients and recommends solutions to ensure fair access to prescription drugs. For more information about ICER, please visit www.icer.org.